57例卵巢癌的预后影响因素分析

目的：探讨卵巢癌的预后影响因素。方法：对1998年1月至2010年12月在我院诊断治疗的57例卵巢癌患者的临床资料进行回顾性分析，比较不同年龄、肿瘤病理类型、临床分期、组织分化程度、残余瘤大小及化疗疗程数问患者的五年生存率。结果：57例中，年龄〉40岁组40例、≤40岁组17例，5年生存率分别为42．5％和47．05％，组间比较差异无统计学意义（P〉0．05）；卵巢上皮性癌45例，非上皮性癌12例，5年生存率分别为44．44％和41．6％，组间比较差异无统计学意义（P〉0．05）。不同组织分化程度（高和中-低）、手术病理分期（Ⅰ-Ⅱ和Ⅲ-Ⅳ期）、残余肿瘤直径（≤2cm和〉2cm）、化疗疗程数（t〉6和〈6个）患者的5年生存率分别为73．33％和33．33％、72．41％和14．29％、53．19％和0、53．85％和22．22％，组间比较差异均有统计学意义（P〈0．05）。结论：年龄、病理类型与卵巢癌预后无关，手术病理分期、组织分化程度、残余肿瘤直径、化疗疗程数是卵巢癌的独立预后影响因素。努力提高卵巢癌的早期诊断、做到早期治疗，术后及时辅以正规、足疗程化疗是提高卵巢癌患者生存率的关键。

Prognostic Factors Analysis in 57 Patients with Ovarian Cancer

Objective：To discuss the influencing factors associated with prognosis of ovarian cancer pa tients. Methods： Clinical data of 57 cases of ovarian cancer diagnosis and treatment in our hospital from January 1998 to December 2010 were retrospectively analyzed , different ages, tumor pathologic type, clinical stage, tissue differentiation degree, residual tumor size and number of chemotherapy treatment between 5 years of sur vival rate of patients were compared. Results：Among the 57 cases, 5 years of survival rate （42.5 % ,47.05% ） between age over 40 years （n =40）and age under 40 years （n = 17）had no statistically significant difference （P 〉 0.05 ） ; 5 years of survival rate （44.44% ,41.6% ）between ovarian epithelial carcinoma （n = 45 ）and non epithelial cancer （n = 12）had no statistically significant difference either （P 〉 0.05 ） ; Different degrees of dif ferentiation （ high and low ）, operation pathological stage （I l] and III IV）, residual tumor diameter （ 〈2 cm and 〉 2 cm） , the number of chemotherapy cycles （〉6 and 〈 6） with a 5 year survival rates were 73.33% and 33.33%, 72.41% , 53.19% and 14.29% and 0, 53.85% and 22.22% respectively, the difference was statistically significant （ P 〈 0.05 ）. Conclusions ： Age, pathological type has nothing to do with the prognosis of ovarian cancer, pathological stage, histological differentiation, residual tumor diameter, number of chemothera py cycles are independent prognostic factors of ovarian cancer. Ovarian cancer early diagnosis, early treatment and regular, full course of postoperative chemotherapy is the key to improving the ovarian cancer survival.